Muscarinic receptors in the thalamus in progressive supranuclear palsy and other neurodegenerative disorders

Journal of Neuropathology and Experimental Neurology

Volumn 66, Issue 5, 2007, Pages 399-404

  Warren, Naomi M ^a   Piggott, Margaret A ^a   Lees, Andrew J ^b   Burn, David J ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b Sara Koe PSP Research Centre   (United Kingdom)

Author keywords

Cholinergic; Muscarinic receptors; Progressive supranuclear palsy; Thalamus

Indexed keywords

MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR DISORDER; BRAIN TISSUE; CHOLINERGIC SYSTEM; CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOTONEURON NUCLEUS; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; SUBTHALAMIC NUCLEUS; THALAMUS NUCLEUS; THALAMUS VENTRAL NUCLEUS;

AGED; AGED, 80 AND OVER; AUTORADIOGRAPHY; FEMALE; HUMANS; MALE; NEURODEGENERATIVE DISEASES; POSTMORTEM CHANGES; PROTEIN BINDING; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M4; SUPRANUCLEAR PALSY, PROGRESSIVE; THALAMUS;

EID: 34247897190     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/nen.0b013e318053db64     Document Type: Article

References (35)

1. Zweig RM, Whitehouse PJ, Casanovas MF, et al. Loss of pedunculopontine neurons in progressive supranuclear palsy. Ann Neurol 1987;22:18-25
2. Albers DS, Augood SJ. New insights into progressive supranuclear palsy. Trends Neurosci 2001;24:347-53
3. Chambers CB, Lee JM, Troncoso JC, Reich S, Muma NA. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Ann Neurol 1999;46:325-32
4. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-81
5. Halliday GM, Macdonald V, Henderson JM. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain 2005;128:2272-80
6. Juh R, Pae CU, Kim TS, et al. Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis. Neurosci Lett 2005;383:22-27
7. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128:1247-58
8. Perry RH. Coronal map of Brodmann areas in the human brain. In: Roberts G, Leigh P, eds. Neuropsychiatric Disorders. London: Wolfe, 1993:1-10
9. Bentovoglio M, Steriade M. Brainstem Diencephalic Circuits as a Structural Substrate of the Ascending Reticular Activation Concept. New York: Raven Press, 1990:7-29
10. Brandel JP, Hirsch EC, Hersh LB, et al. Compartmental ordering of cholinergic innervation in the mediodorsal nucleus of the thalamus in human brain. Brain Res 1990;515:117-25
11. 3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice. Brain Res Mol Brain Res 2005;133:6-11
12. Piggott M, Owens J, O'Brien J, et al. Comparative distribution of binding of the muscarinic receptor ligands pirenzepine, AF-DX 384, (R,R)-I-QNB and (R,S)-I-QNB to human brain. J Chem Neuroanat 2002;24:211-23
13. Bernard V, Normand E, Bloch B. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J Neurosci 1992;12:3591-600
14. Ince E, Ciliax BJ, Levey AI. Differential expression of D1 and D2 dopamine and M4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons. Synapse 1997;27:357-66
15. Hoover DB, Baisden RH. Localization of putative cholinergic neurons innervating the anteroventral thalamus. Brain Res Bull 1980;5:519-24
16. Lee MS, Rinne JO, Marsden CD. The pedunculopontine nucleus: Its role in the genesis of movement disorders. Yonsei Med J 2000;41:167-84
17. Kasashima S, Oda Y. Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 2003;105:117-24
18. Xuereb JH, Perry EK, Candy JM, et al. Parameters of cholinergic neurotransmission in the thalamus in Parkinson's disease and Alzheimer's disease. J Neurol Sci 1990;99:185-97
19. Cavada C, Company T, Hernandez-Gonzalez A, et al. Acetylcholinesterase histochemistry in the macaque thalamus reveals territories selectively connected to frontal, parietal and temporal association cortices. J Chem Neuroanat 1995;8:245-57
20. Brandel JP, Hirsch EC, Malessa S, et al. Differential vulnerability of cholinergic projections to the mediodorsal nucleus of the thalamus in senile dementia of Alzheimer type and progressive supranuclear palsy. Neuroscience 1991;41:25-31
21. Giguere M, Goldman-Rakic PS. Mediodorsal nucleus: Areal, laminar, and tangential distribution of afferents and efferents in the frontal lobe of rhesus monkeys. J Comp Neurol 1988;277:195-213
22. Shook BL, Schlag-Rey M, Schlag J. Primate supplementary eye field. II. Comparative aspects of connections with the thalamus, corpus striatum, and related forebrain nuclei. J Comp Neurol 1991;307:562-83
23. Henderson JM, Carpenter K, Cartwright H, et al. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: Clinical and therapeutic implications. Brain 2000;123:1410-21
24. DeVito JL, Anderson ME. An autoradiographic study of efferent connections of the globus pallidus in Macaca mulatta. Exp Brain Res 1982;46:107-17
25. Strick PL. Anatomical analysis of ventrolateral thalamic input to primate motor cortex. J Neurophysiol 1976:39:1020-31
26. Schell GR, Strick PL. The origin of thalamic inputs to the arcuate premotor and supplementary motor areas. J Neurosci 1984;4:539-60
27. Ziabreva I, Ballard CG, Aarsland D, et al. Lewy body disease: Thalamic cholinergic activity related to dementia and parkinsonism. Neurobiol Aging 2006;27:433-38
28. 125I]α-conotoxin MII in the striatum and thalamus. Exp Neurol 2005;191:292-300
29. Vogt BA, Crino PB, Vogt LJ. Reorganization of cingulate cortex in Alzheimer's disease: Neuron loss, neuritic plaques, and muscarinic receptor binding. Cereb Cortex 1992;2:526-35
30. Parent A, Hazrati LN. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Brain Res Rev 1995;20:128-54
31. Kita H, Kitai ST. Efferent projections of the subthalamic nucleus in the rat: Light and electron microscopic analysis with the PHA-L method. J Comp Neurol 1987;260:435-52
32. Wichmann T, DeLong MR. Pathophysiology of parkinsonian motor abnormalities. Adv Neurol 1993;60:53-61
33. Rodriguez-Puertas R, Pascual J, Pazos A. Effects of freezing storage time on the density of muscarinic receptors in the human postmortem brain: An autoradiographic study in control and Alzheimer's disease brain tissues. Brain Res 1996;728:65-71
34. Piggott MA, Owens J, O'Brien J, et al. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease. J Chem Neuroanat 2003;25:161-73
35. Burn DJ, Warren NM. Toward future therapies in progressive supranuclear palsy. Mov Disord 2005;20(Suppl 12):S92-98